Back to search results

Ultromics EchoGo for Heart Failure Risk in Type 2 Diabetes

This study is testing if a special computer alert can help doctors identify and treat patients with type 2 diabetes who are at high risk for a type of heart failure called HFpEF (Heart Failure with preserved ejection fraction). The alert uses a tool called Ultromics EchoGo to analyze past echocardiograms (heart ultrasounds). If the EchoGo tool finds signs of HFpEF, the doctor gets a message with recommendations for treatments like SGLT-2i medication (a type of diabetes drug that can also help the heart). The study wants to see if doctors prescribe these medications more often when they receive this alert. You might be able to join if you have type 2 diabetes, a high WATCH DM score, and had an echocardiogram in the last 6 months, and no history of heart failure. The study is currently unclear on its recruitment status.

Study design
This is a randomized study involving 800 participants. It's designed to compare how doctors respond to different types of computer alerts.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will follow up on medication prescriptions for 3 and 6 months after the alert. It will also track hospitalizations for heart failure within 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06593314

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

Recruiting
NAAll AgesInterventionalPrevention
University of Texas Southwestern Medical Center
~800 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Message with EchoGoStandard Message

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up
Measured over 3-month follow-up
+1 more outcome measured

Conditions

Heart Failure
Diabetes

Explore related trials

Heart FailureType 2 Diabetes Mellitus

NCT06593314

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UT Southwestern Medical Center

    Dallas, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ambarish Pandey, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Ambarish Pandey, MD
[email protected]
617-869-8957
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
Echocardiogram available in last 6-months.

Exclusion

History of HF
Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA

What this trial measures

  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up3-month follow-up

    Frequency of prescription of SGLT-2i medication at outpatient clinic visits will be measured as the proportion of new prescription for SGLT2inhibitor divided by the number of alerts triggered.

  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up3-month follow-up

    Frequency of prescription of SGLT-2i medication at outpatient clinic visits will be measured as the proportion of new prescription for GLP1 divided by the number of alerts triggered.